Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Soft Tissue Neoplasms | 5 | 2023 | 56 | 3.000 |
Why?
|
| Sarcoma | 4 | 2023 | 65 | 2.230 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2024 | 1529 | 1.310 |
Why?
|
| Diagnostic Imaging | 4 | 2023 | 179 | 1.310 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2021 | 196 | 1.240 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 331 | 1.130 |
Why?
|
| Radiology | 3 | 2024 | 130 | 0.850 |
Why?
|
| Diabetic Foot | 1 | 2023 | 46 | 0.820 |
Why?
|
| Musculoskeletal System | 1 | 2022 | 16 | 0.790 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2021 | 4 | 0.780 |
Why?
|
| Osteomyelitis | 1 | 2023 | 125 | 0.760 |
Why?
|
| Fibroma | 1 | 2021 | 39 | 0.750 |
Why?
|
| Tuberous Sclerosis | 1 | 2021 | 36 | 0.750 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 57 | 0.670 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 281 | 0.660 |
Why?
|
| Muscular Diseases | 2 | 2014 | 61 | 0.570 |
Why?
|
| Infarction | 1 | 2014 | 14 | 0.480 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 201 | 0.390 |
Why?
|
| Pelvis | 3 | 2022 | 67 | 0.390 |
Why?
|
| Humans | 21 | 2024 | 50201 | 0.370 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2024 | 57 | 0.370 |
Why?
|
| Pelvic Organ Prolapse | 2 | 2021 | 28 | 0.360 |
Why?
|
| Abdomen | 2 | 2020 | 77 | 0.330 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 459 | 0.280 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 1160 | 0.250 |
Why?
|
| Radiography | 3 | 2022 | 485 | 0.240 |
Why?
|
| Diabetes Complications | 2 | 2014 | 118 | 0.220 |
Why?
|
| Pelvic Floor | 2 | 2021 | 51 | 0.220 |
Why?
|
| Observer Variation | 1 | 2024 | 136 | 0.220 |
Why?
|
| Ankle | 1 | 2023 | 11 | 0.220 |
Why?
|
| Tendons | 1 | 2023 | 27 | 0.210 |
Why?
|
| Liposarcoma | 1 | 2023 | 22 | 0.210 |
Why?
|
| Lordosis | 1 | 2022 | 4 | 0.200 |
Why?
|
| Kyphosis | 1 | 2022 | 15 | 0.200 |
Why?
|
| Lower Extremity | 1 | 2023 | 92 | 0.200 |
Why?
|
| Immunohistochemistry | 2 | 2021 | 973 | 0.190 |
Why?
|
| Osteoarthritis, Knee | 1 | 2022 | 89 | 0.190 |
Why?
|
| Bone Marrow | 1 | 2023 | 356 | 0.180 |
Why?
|
| Pelvic Floor Disorders | 1 | 2021 | 29 | 0.180 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2020 | 5 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2020 | 8 | 0.180 |
Why?
|
| Sarcoma, Ewing | 1 | 2020 | 27 | 0.170 |
Why?
|
| Spinal Nerves | 1 | 2018 | 10 | 0.160 |
Why?
|
| Facial Pain | 1 | 2018 | 9 | 0.160 |
Why?
|
| Cranial Nerves | 1 | 2018 | 14 | 0.160 |
Why?
|
| Neck Pain | 1 | 2018 | 10 | 0.160 |
Why?
|
| Cranial Nerve Diseases | 1 | 2018 | 15 | 0.160 |
Why?
|
| Cartilage Diseases | 1 | 2018 | 11 | 0.150 |
Why?
|
| Menisci, Tibial | 1 | 2018 | 11 | 0.150 |
Why?
|
| Algorithms | 1 | 2021 | 615 | 0.140 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 424 | 0.140 |
Why?
|
| Osteoarthritis | 1 | 2018 | 61 | 0.140 |
Why?
|
| Databases, Factual | 1 | 2020 | 660 | 0.140 |
Why?
|
| Transcription Factors | 1 | 2020 | 563 | 0.140 |
Why?
|
| Reproducibility of Results | 3 | 2024 | 1195 | 0.130 |
Why?
|
| Male | 6 | 2024 | 25572 | 0.120 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 1580 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1041 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2021 | 3896 | 0.100 |
Why?
|
| Adult | 5 | 2024 | 13486 | 0.100 |
Why?
|
| Defecography | 2 | 2021 | 16 | 0.090 |
Why?
|
| Retrospective Studies | 4 | 2024 | 6190 | 0.090 |
Why?
|
| Female | 6 | 2024 | 26829 | 0.070 |
Why?
|
| Extremities | 1 | 2024 | 30 | 0.060 |
Why?
|
| Radiology Information Systems | 1 | 2024 | 31 | 0.060 |
Why?
|
| Musculoskeletal Diseases | 1 | 2024 | 47 | 0.060 |
Why?
|
| Middle Aged | 3 | 2024 | 12356 | 0.050 |
Why?
|
| Technology | 1 | 2022 | 20 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2023 | 125 | 0.050 |
Why?
|
| Lumbar Vertebrae | 1 | 2022 | 99 | 0.050 |
Why?
|
| Teaching | 1 | 2022 | 113 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2024 | 397 | 0.040 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2020 | 8 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 959 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2023 | 871 | 0.040 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2020 | 14 | 0.040 |
Why?
|
| Aged | 2 | 2024 | 9505 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2020 | 32 | 0.040 |
Why?
|
| Cyclin D1 | 1 | 2020 | 56 | 0.040 |
Why?
|
| Learning | 1 | 2022 | 158 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 121 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 109 | 0.040 |
Why?
|
| Skull Base | 1 | 2018 | 32 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 487 | 0.030 |
Why?
|
| Thigh | 1 | 2014 | 34 | 0.030 |
Why?
|
| Necrosis | 1 | 2014 | 175 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2020 | 5203 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 6459 | 0.020 |
Why?
|